**Supplementary Table S1. Primary human Ph+ ALL samples**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ID sample** | **BCR-ABL1** | **Age** | **Source** | **Previous TKI** **Therapy** |  **Cytogenetics** |
| ALL-1006 | p190 | 65 | BM | No | 45,XY,t(9;22)(q34;q11.2),add(16)(q22),-20[17]/45,idem,add(12)(q13),-18,+20[2]/46,XY[1] |
| ALL-1539 | p190 | 76 | PB | No | 46,XX,t(9;22)(q34;q11.2)[16]/nonclonal w/clonal abnormalities[2]/46,XX[2] |
| ALL-10463 | p190 | 41 | BM | No | 46,XX,t(9;22)(q34;q11)[10]/46,XX[13] |
| ALL-004 | p190 | 53 | PB | No | 80% CDKN2A deletion88% KMT2A (MLL, 11q23) deletion;5% positive for rearrangement of KMT2A (MLL);65% 5’ IGH deletion;25% IGH (14q32) deletion |
| ALL-011 | p190 | 41 | PB | No | Borderline positive (2%) for rearrangement of KMT2A (MLL) |
| ALL-358 | p190 | 58 | PB | No | NA |
| ALL-3934 | p190 | 45 | BM | No | NA |
| ALL-536 | p210 |  |  | No | NA |
| ALL-3961 | p190 | 42 | PB | Yes | Relapse, T315I mutation in the TKD |
| ALL-11463 | p190 | 34 | PB | Yes | Relapse, no mutation found in the TKD |
| ALL-5775 | p210 | 61 | PB | Yes | Relapse |
| ALL-1577 | p190 | 65 | PB | Yes | Relapse, no mutation found in the TKD |
| ALL-2534 | p190 | 57 | PB | Yes | Relapse, no mutation found in the TKD |
| ALL-557 | p210 | NA | NA | Yes | Relapse, T315I mutation in the TKD |
| ALL-27574 | p190 | 32 | PB | Yes | Relapse, Q252H mutation in the TKD (described by Zabriskie/Eide et al., 2014 and Gibbons et al., 2011) |

BM = bone marrow; PB = peripheral blood; NA = information not available; TKD = Tyrosine Kinase Domain